FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD
The Dermatology Digest
FEBRUARY 14, 2024
This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.
Let's personalize your content